Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2000 Apr;68(4):479–482. doi: 10.1136/jnnp.68.4.479

Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone

F Keime-Guibert 1, F Graus 1, A Fleury 1, R Rene 1, J Honnorat 1, P Broet 1, J Delattre 1
PMCID: PMC1736897  PMID: 10727484

Abstract

OBJECTIVES—To evaluate the effect of a combination of immunoglobulins (IVIg), cyclophosphamide (CTX), and methylprednisolone (MP) on the clinical course of patients with paraneoplastic neurological syndrome (PNS) and antineuronal antibodies (Abs).
METHODS—Seventeen patients with paraneoplastic encephalomyelitis/sensory neuropathy (PEM/SN) with anti-Hu Abs (n=10) or cerebellar degeneration (PCD) with anti-Yo Abs (n=7) received one to nine cycles (mean 3.5) of a combination of IVIg (0.5 g/kg/day from days 1 to 5), CTX (600 mg/m2 at day 1) and MP (1g/day from day 1 to 3). The Rankin scale (RS) was used to evaluate the response. A positive response was considered as either improvement or stabilisation in patients who were still ambulatory (RS⩽3) at the onset of treatment, whereas only improvement, and not stabilisation, was considered a therapeutic benefit in bedridden patients (RS⩾4).
RESULTS—Tolerance was good and no patient experienced grade 3/4 toxicity (World Health Organisation). Sixteen patients were evaluable for response. Of the seven patients with RS⩾4, none improved. Of the nine patients with RS⩽3, none improved but three (two SN and one PCD) stabilised for 4, 35, and 16months.
CONCLUSIONS—This study suggests that vigorous immunosuppressive treatment is not useful in severely disabled PNS patients with antineuronal Abs. In a minority of patients (mainly with SN) who are not severely disabled at the onset of treatment, a transient stabilisation is possible and deserves further evaluation.



Full Text

The Full Text of this article is available as a PDF (118.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Byrne T., Mason W. P., Posner J. B., Dalmau J. Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry. 1997 Mar;62(3):276–278. doi: 10.1136/jnnp.62.3.276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chalk C. H., Murray N. M., Newsom-Davis J., O'Neill J. H., Spiro S. G. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology. 1990 Oct;40(10):1552–1556. doi: 10.1212/wnl.40.10.1552. [DOI] [PubMed] [Google Scholar]
  3. Counsell C. E., McLeod M., Grant R. Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurology. 1994 Jun;44(6):1184–1185. doi: 10.1212/wnl.44.6.1184. [DOI] [PubMed] [Google Scholar]
  4. Dalmau J., Graus F., Rosenblum M. K., Posner J. B. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992 Mar;71(2):59–72. doi: 10.1097/00005792-199203000-00001. [DOI] [PubMed] [Google Scholar]
  5. David Y. B., Warner E., Levitan M., Sutton D. M., Malkin M. G., Dalmau J. O. Autoimmune paraneoplastic cerebellar degeneration in ovarian carcinoma patients treated with plasmapheresis and immunoglobulin. A case report. Cancer. 1996 Nov 15;78(10):2153–2156. [PubMed] [Google Scholar]
  6. Furneaux H. F., Reich L., Posner J. B. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology. 1990 Jul;40(7):1085–1091. doi: 10.1212/wnl.40.7.1085. [DOI] [PubMed] [Google Scholar]
  7. Glantz M. J., Biran H., Myers M. E., Gockerman J. P., Friedberg M. H. The radiographic diagnosis and treatment of paraneoplastic central nervous system disease. Cancer. 1994 Jan 1;73(1):168–175. doi: 10.1002/1097-0142(19940101)73:1<168::aid-cncr2820730129>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  8. Graus F., Bonaventura I., Uchuya M., Valls-Solé J., Reñ R., Leger J. M., Tolosa E., Delattre J. Y. Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology. 1994 Dec;44(12):2258–2261. doi: 10.1212/wnl.44.12.2258. [DOI] [PubMed] [Google Scholar]
  9. Graus F., Vega F., Delattre J. Y., Bonaventura I., Reñ R., Arbaiza D., Tolosa E. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology. 1992 Mar;42(3 Pt 1):536–540. doi: 10.1212/wnl.42.3.536. [DOI] [PubMed] [Google Scholar]
  10. Hammer M. S., Larsen M. B., Stack C. V. Outcome of children with opsoclonus-myoclonus regardless of etiology. Pediatr Neurol. 1995 Jul;13(1):21–24. doi: 10.1016/0887-8994(95)00083-r. [DOI] [PubMed] [Google Scholar]
  11. Hommes O. R., Lamers K. J., van Geel W. Intrathecal IgG synthesis and IgG index after intensive and chronic immunosuppressive treatment of multiple sclerosis. Ann N Y Acad Sci. 1984;436:410–417. doi: 10.1111/j.1749-6632.1984.tb14812.x. [DOI] [PubMed] [Google Scholar]
  12. Moll J. W., Henzen-Logmans S. C., Van der Meché F. G., Vecht C. H. Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):112–112. doi: 10.1136/jnnp.56.1.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Newsom-Davis J., Murray N. M. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology. 1984 Apr;34(4):480–485. doi: 10.1212/wnl.34.4.480. [DOI] [PubMed] [Google Scholar]
  14. Oh S. J., Dropcho E. J., Claussen G. C. Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve. 1997 Dec;20(12):1576–1582. [PubMed] [Google Scholar]
  15. Schuller E. A., Benabdallah S., Sagar H. J., Reboul J. A., Tömpe L. C. IgG synthesis within the central nervous system. Comparison of three formulas. Arch Neurol. 1987 Jun;44(6):600–604. doi: 10.1001/archneur.1987.00520180024010. [DOI] [PubMed] [Google Scholar]
  16. Stark E., Wurster U., Patzold U., Sailer M., Haas J. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol. 1995 Aug;52(8):814–818. doi: 10.1001/archneur.1995.00540320098016. [DOI] [PubMed] [Google Scholar]
  17. Uchuya M., Graus F., Vega F., Reñ R., Delattre J. Y. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996 Apr;60(4):388–392. doi: 10.1136/jnnp.60.4.388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Vega F., Graus F., Chen Q. M., Poisson M., Schuller E., Delattre J. Y. Intrathecal synthesis of the anti-Hu antibody in patients with paraneoplastic encephalomyelitis or sensory neuronopathy: clinical-immunologic correlation. Neurology. 1994 Nov;44(11):2145–2147. doi: 10.1212/wnl.44.11.2145. [DOI] [PubMed] [Google Scholar]
  19. Verschuuren J., Twijnstra A., De Baets M., Thunnissen F., Dalmau J., van Breda Vriesman P. Hu antigens and anti-Hu antibodies in a patient with myxoid chondrosarcoma. Neurology. 1994 Aug;44(8):1551–1552. doi: 10.1212/wnl.44.8.1551. [DOI] [PubMed] [Google Scholar]
  20. Yagi Y., Inuzuka T., Takada K., Nakano R., Hozumi I., Yoshimoto H., Onodera O., Tanaka K., Sato S., Takahashi M. Changes in anti-HuD antibody titers in the long-term course in paraneoplastic sensory neuropathy. Eur Neurol. 1997;37(2):122–123. doi: 10.1159/000117422. [DOI] [PubMed] [Google Scholar]
  21. Younger D. S., Dalmau J., Inghirami G., Sherman W. H., Hays A. P. Anti-Hu-associated peripheral nerve and muscle microvasculitis. Neurology. 1994 Jan;44(1):181–183. doi: 10.1212/wnl.44.1.181-a. [DOI] [PubMed] [Google Scholar]
  22. van Doorn P. A., Brand A., Strengers P. F., Meulstee J., Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology. 1990 Feb;40(2):209–212. doi: 10.1212/wnl.40.2.209. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES